Neuroprotective effects of atomoxetine against traumatic spinal cord injury in rats

Document Type : Original Article

Authors

1 Department of Orthopedics, Hospital of Qingdao University, Qingdao, Shandong, 266000, China

2 Department of Pharmacy, Qilu Hospital of Shandong University (Qingdao Hospital District),Qingdao, Shandong, 266000, China

Abstract

Objective(s):Spinal cord injury (SCI) often causes serious and irreversible neurological deficit leading to disability or impairment of normal physical activity. Atomoxetine, a selective norepinephrine transporter (NET) inhibitor has gained much attention in the field of the neurodevelopmental disorder, but its effect on SCI has not been evaluated. The present study has been undertaken to investigate the neuroprotective effects of atomoxetine.
Materials and Methods: Administration of atomoxetine 20 mg/kg IP was compared with methylprednisolone (MP) 30 mg/kg IP in traumatic spinal cord injured Wistar rats. Tissue samples were evaluated for apoptosis, inflammation, and oxidative stress, along with histopathological examination and neurological evaluation.
Results: There was no significant difference in the caspase-3 activity between the control and the sham groups or between the MP and the atomoxetine groups (P=0.811). The administration of atomoxetine significantly reduced tissue tumour necrosis factor alpha (TNF-α), and nitric oxide (NO) levels compared to the trauma group (P<0.001). Treatment with atomoxetine also decreased the tissue myeloperoxidase (MPO) activity (P=0.026) and increased the tissue superoxide dismutase (SOD) activity compared to the trauma group (P=0.001 and P=0.004, respectively). Histopathological examination showed less degenerated neurons in the atomoxetine group compared to trauma group.
Conclusion: This is the first experimental evidence showing meaningful neuroprotective effects of atomoxetine over SCI through anti-apoptotic, anti-inflammatory, and antioxidant effects by reducing lipid peroxidation, which was confirmed by biochemical, histopathological and the functional evaluation.

Keywords

References

1. Dumont RJ, Okonkwo DO, Verma S, Hurlbert RJ, Boulos PT, Ellegala DB, et al. Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol 2001; 24:254-264.
2. Mautes AE, Weinzierl MR, Donovan F, Noble LJ. Vascular events after spinal cord injury: contribution to secondary pathogenesis. Phys Ther 2000; 80:673-687.
3. Blight AR. Macrophages and inflammatory damage in spinal cord injury. J Neurotrauma 1992; 9:S83-S91.
4. Cemil B, Topuz K, Demircan MN, Kurt G, Tun K, Kutlay M, et al. Curcumin improves early functional results after experimental spinal cord injury. Acta Neurochir (Wien ) 2010; 152:1583-1590.
5. Esposito E, Rinaldi B, Mazzon E, Donniacuo M, Impellizzeri D, Paterniti I, et al. Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-alpha. J Neuroinflamm 2012; 9:81.
6. Pannu R, Barbosa E, Singh AK, Singh I. Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats. J Neurosci Res 2005; 79:340-350.
7. Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 2003; 4:1165–1174.
8. Pataki CS, Feinberg DT, McGough JJ. New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs 2004; 9:293-302.
9. Gehlert DR, Gackenheimer SL, Robertson DW. Localization of rat brain binding sites for [3H]atomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett 1993; 157:203-206.
10. Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 2006; 50:755-760.
11. Kurt G, Ergun E, Cemil B, Borcek AO, Borcek P, Gulbahar O, et al. Neuroprotective effects of infliximab in experimental spinal cord injury. Surg Neurol 2009; 71:332-336.
12. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95:351-358.
13. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001; 5:62-71.
14. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34:497-500.
15. Kertmen H, Gurer B, Yilmaz ER, Sanli AM, Sorar M, Arikok AT, et al. The protective effect of low-dose methotrexate on ischemia-reperfusion injury of the rabbit spinal cord. Eur J Pharmacol 2013; 714:148-156.
16. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995; 12:1-21.
17. Z'Graggen WJ, Metz GA, Kartje GL, Thallmair M, Schwab ME. Functional recovery and enhanced corticofugal plasticity after unilateral pyramidal tract lesion and blockade of myelin-associated neurite growth inhibitors in adult rats. J Neurosci 1998; 18:4744-4757.
18. Beattie MS, Hermann GE, Rogers RC, Bresnahan JC. Cell death in models of spinal cord injury. Prog Brain Res 2002; 137:37-47.
19. Hulsebosch CE. Recent advances in pathophysiology and treatment of spinal cord injury. Adv Physiol Educ 2002; 26:238-255.
20. Dinc C, Iplikcioglu AC, Atabey C, Eroglu A, Topuz K, Ipcioglu O, et al. Comparison of deferoxamine and methylprednisolone: protective effect of pharmacological agents on lipid peroxidation in spinal cord injury in rats. Spine 2013; 38:E1649-E1655.
21. Sauer JM, Ring BJ, Witcher JW. Clinical pharmaco-kinetics of atomoxetine. Clin Pharmacokinet 2005; 44:571-590.
22. Ripley DL. Atomoxetine for individuals with traumatic brain injury. J Head Trauma Rehabil 2006; 21:85-88.
23. Gould TJ, Rukstalis M, Lewis MC. Atomoxe-tine and   nicotine  enhance prepulse inhibition  of   acoustic startle in C57BL/6 mice. Neurosci Lett 2005; 377:85-90.
24. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27:699–711.
25. Hurlbert RJ, Hamilton MG. Methylprednisolone for acute spinal cord injury: 5-year practice reversal. Can J Neurol Sci 2008; 35:41-45.
26. Schroter A, Lustenberger RM, Obermair FJ, Thallmair M. High-dose corticosteroids after spinal cord injury reduce neural progenitor cell proliferation. Neuroscience 2009; 161:753-763.
27. Balentine JD. Pathology of experimental spinal cord trauma. I. The necrotic lesion as a function of vascular injury. Lab Invest 1978; 39:236-253.
28. Borgens RB, Blight AR, Murphy DJ. Axonal regeneration in spinal cord injury: a perspective and new technique. J Comp Neurol 1986; 250:157-167.
29. Liu XZ, Xu XM, Hu R, Du C, Zhang SX, McDonald JW, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci 1997; 17:5395-5406.
30. Pannu R, Christie DK, Barbosa E, Singh I, Singh AK. Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J Neurochem 2007; 101:182-200.
31. Keane RW, Kraydieh S, Lotocki G, Bethea JR, Krajewski S, Reed JC, et al. Apoptotic and anti-apoptotic mechanisms following spinal cord injury. J Neuropathol Exp Neurol 2001; 60:422-429.
32. Sakurai M, Nagata T, Abe K, Horinouchi T, Itoyama Y, Tabayashi K. Survival and death-promoting events after transient spinal cord ischemia in rabbits: induction of Akt and caspase3 in motor neurons. J Thorac Cardiovasc Surg 2003; 125:370-377.
33. Hayashi M, Ueyama T, Nemoto K, Tamaki T, Senba E. Sequential mRNA expression for immediate early genes, cytokines, and neurotrophins in spinal cord injury. J Neurotrauma 2000; 17:203-218.
34. Pan W, Zhang L, Liao J, Csernus B, Kastin AJ. Selective increase in TNF alpha permeation across the blood-spinal cord barrier after SCI. J Neuroimmunol 2003; 134:111-117.
35. Bao F, Chen Y, Dekaban GA, Weaver LC. Early anti-inflammatory treatment reduces lipid peroxidation and protein nitration after spinal cord injury in rats. J Neurochem 2004; 88:1335-1344.
36. Christie SD, Comeau B, Myers T, Sadi D, Purdy M, Mendez I. Duration of lipid peroxidation after acute spinal cord injury in rats and the effect of methylprednisolone. Neurosurg Focus 2008; 25:E5.
37. Torres S, Salgado-Ceballos H, Torres JL, Orozco-Suarez S, Diaz-Ruiz A, Martinez A, et al. Early metabolic reactivation versus antioxidant therapy after a traumatic spinal cord injury in adult rats. Neuropathology 2010; 30:36-43.
38. Somkuwar SS, Jordan CJ, Kantak KM, Dwoskin LP. Adolescent Atomoxetine Treatment in a Rodent Model of ADHD: Effects on Cocaine Self-Administration and Dopamine Transporters in Frontostriatal Regions. Neuropsychopharmacology 2013; 38:2588–2597.
39. Dawson TM, Dawson VL, Snyder SH. Molecular mechanisms of nitric oxide actions in the brain. Ann N Y Acad Sci 1994; 738:76-85.
40. Hulsebosch CE, DeWitt DS, Jenkins LW, Prough DS. Traumatic brain injury in rats results in increased expression of Gap-43 that correlates with behavioral recovery. Neurosci Lett 1998; 255:83-86.
Iranian Journal of Basic Medical Sciences
Volume 19, Issue 3
March 2016
Pages 272-280

Files

Share

How to cite

Statistics